NEOCARDIABCARE DIVISION OF FINECURE PHARMA
Finecure Pharmaceuticals, the flagship company of the Finecure Group, has expanded its horizons beyond its core business into the therapeutic segments of cardiovascular and diabetology. The establishment of the 'Neocardiabcare' Division in 2014 was a strategic move aimed at manufacturing formulations specifically for cardiovascular and anti-diabetic therapeutic segments. This initiative complements Finecure Pharmaceuticals' extensive range of pharmaceutical products across various remedial sectors. The decision to venture into these segments was prompted by the alarming rise in cardiovascular diseases, particularly among the young population in India. With cardiovascular disease, including diabetes, emerging as the leading cause of death globally, Finecure Pharmaceuticals recognized the urgent need to address this issue. Unhealthy eating habits and sedentary lifestyles have contributed to a surge in heart ailments among individuals in their 20s, 30s, and 40s, posing a significant socio-economic burden on individuals, families, and the nation at large. The vision of the 'Neocardiabcare' Division is to become a trusted provider of affordable, qualitative, and accessible cardiac and diabetes healthcare solutions. With a focus on advancing patient care through high-quality yet affordable pharmaceutical products, the division has garnered trust and success since its inception. By continuously refining technologies and introducing new developments, Finecure Pharmaceuticals is committed to contributing to a healthier society and nation.
